dRx Capital

dRx Capital is the dedicated digital health venture capital arm of Novartis, a global pharmaceutical giant headquartered in Basel, Switzerland. Established to identify and invest in groundbreaking early-stage digital health companies, dRx Capital plays a crucial role in Novartis's broader strategy to transform healthcare through innovation. The fund operates with a dual mandate: to generate financial returns while also fostering strategic alignment with Novartis’s core business objectives, leveraging digital technologies to enhance patient outcomes, streamline drug development, and improve healthcare delivery worldwide.

The firm primarily targets Seed, Series A, and Series B funding rounds, focusing on startups that are developing disruptive solutions in areas such as artificial intelligence, data analytics, remote patient monitoring, digital therapeutics, and decentralized clinical trials. Their investment thesis centers on technologies that can significantly impact chronic disease management, personalized medicine, and patient engagement. As of early 2024, dRx Capital boasts a robust portfolio of 23 companies, demonstrating its active presence and commitment to the digital health ecosystem.

dRx Capital provides more than just capital; it offers portfolio companies access to Novartis’s extensive global network, deep scientific expertise, and regulatory insights, facilitating strategic partnerships and accelerating market adoption. The fund has been an active participant in significant early-stage rounds, for instance, contributing to Series A rounds that have often ranged from $10 million to $20 million for promising ventures. This strategic involvement underscores their commitment to supporting the growth of innovative digital health solutions that align with Novartis's vision for the future of medicine.